Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Acq. announced
Director departure
|
|
Graf Acquisition Corp. IV
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Director compensation was amended/approved, Acquisition/merger/asset purchase announced|
Docs:
|
"Amended and Restated Certificate of Incorporation of NKGen Biotech, Inc",
"Amended and Restated Bylaws of NKGen Biotech, Inc",
"Specimen Common Stock Certificate",
"Specimen Warrant Certificate",
"June 26, 2023",
"Amended and Restated Registration Rights Agreement, by and among NKGen Biotech, Inc., members of Graf Acquisition Partners IV LLC, and certain former stockholders of NKGen Operating Biotech, Inc",
"THIRD AMENDED AND RESTATED SPONSOR SUPPORT AND LOCKUP AGREEMENT",
"SECOND AMENDED AND RESTATED SPONSOR SUPPORT AND LOCKUP AGREEMENT",
"Promissory Note issued by NKGen Biotech, Inc. to Lisa J. Ling",
"June 26, 2023" |
|
| 09/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"Form of Additional Warrant Subscription Agreement",
"Amended and Restated Warrant Subscription Agreement",
"Forward Purchase Agreement, by and among Graf, Legacy NKGen and Sandia Investment Management LP and certain other affiliates",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"EACH PARTY HEREBY WAIVES ITS RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OR RELATED TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IN ANY ACTION, PROCEEDING OR OTHER LITIGATION OF ANY TYPE BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY OR ANY AFFILIATE OF ANY OTHER SUCH PARTY, WHETHER WITH RESPECT TO CONTRACT CLAIMS, TORT CLAIMS OR OTHERWISE. THE PARTIES AGREE THAT ANY SUCH CLAIM OR CAUSE OF ACTION SHALL BE TRIED BY A COURT TRIAL WITHOUT A JURY. WITHOUT LIMITING THE FOREGOING, THE PARTIES FURTHER AGREE THAT THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY IS WAIVED BY OPERATION OF THIS SECTION AS TO ANY ACTION, COUNTERCLAIM OR OTHER PROCEEDING WHICH SEEKS, IN WHOLE OR IN PART, TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF T..." |
|
| 09/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 08/15/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
8-K
| Quarterly results |
| 05/31/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/22/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 03/24/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"About NKGen Biotech, Inc. NKGen Biotech, Inc. is a clinical-stage biotechnology company incorporated as a Delaware corporation and focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer cell therapeutics. The company is headquartered in Santa Ana, CA. Graf Acquisition Corp. is a blank-check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Important Information and Where to Find It If a legally binding definitive agreement with respect to the proposed business combination is executed, Graf intends to file with the U.S. Securities and Exchange Commission a regist..." |
|
| 12/21/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/30/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 07/14/2021 |
8-K
| Quarterly results |
| 07/09/2021 |
8-K
| Quarterly results |
| 06/04/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
8-K
| Quarterly results |
|
|